{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:37:16Z","timestamp":1778715436820,"version":"3.51.4"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychosomatics"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.psym.2019.11.002","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T19:40:58Z","timestamp":1573760458000},"page":"105-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Neuroendocrine Disturbances in Neurodegenerative Disorders: A Scoping Review"],"prefix":"10.1016","volume":"61","author":[{"given":"Amy","family":"Newhouse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeina","family":"Chemali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.psym.2019.11.002_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol"},{"key":"10.1016\/j.psym.2019.11.002_bib2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/jrsm.1123","article-title":"A\u00a0scoping review of scoping reviews: advancing the approach and enhancing the consistency","volume":"5","author":"Pham","year":"2014","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.psym.2019.11.002_bib3","doi-asserted-by":"crossref","first-page":"b158","DOI":"10.1136\/bmj.b158","article-title":"Alzheimer\u2019s disease","volume":"338","author":"Burns","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.psym.2019.11.002_bib4","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1212\/01.WNL.0000129697.01779.0A","article-title":"The importance of neuritic plaques and tangles to the development and evolution of AD.","volume":"62","author":"Tiraboschi","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.psym.2019.11.002_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer\u2019s disease: a review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"Suppl 9","key":"10.1016\/j.psym.2019.11.002_bib6","first-page":"7","article-title":"Neuropathologic changes in Alzheimer\u2019s disease","volume":"64","author":"Wenk","year":"2003","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psym.2019.11.002_bib7","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3233\/JAD-2010-100663","article-title":"HPA axis dysregulation associated to apolipoprotein E4 genotype in Alzheimer\u2019s disease","volume":"22","author":"Gil-Bea","year":"2010","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.psym.2019.11.002_bib8","first-page":"120","article-title":"Therapeutic implications of HPA axis abnormalities in Alzheimer\u2019s disease: review and update","volume":"37","author":"Pomara","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.psym.2019.11.002_bib9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.brainres.2007.05.027","article-title":"The relation of cortisol levels with hippocampus volumes under baseline and challenge conditions","volume":"1179","author":"Tessner","year":"2007","journal-title":"Brain Res"},{"key":"10.1016\/j.psym.2019.11.002_bib10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1176\/ajp.143.3.300","article-title":"Cortisol and Alzheimer\u2019s disease, I: basal studies","volume":"143","author":"Davis","year":"1986","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psym.2019.11.002_bib11","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1176\/ajp.139.11.1468","article-title":"Dexamethasone suppression test and cortisol circadian rhythm in primary degenerative dementia","volume":"139","author":"Raskind","year":"1982","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psym.2019.11.002_bib12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1176\/ajp.149.4.546","article-title":"Agitation and postdexamethasone cortisol levels in Alzheimer\u2019s disease","volume":"149","author":"Lawlor","year":"1992","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psym.2019.11.002_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.mp.4002101","article-title":"The amyloidogenic potential and behavioral correlates of stress","volume":"14","author":"Catania","year":"2007","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.psym.2019.11.002_bib14","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1523\/JNEUROSCI.2797-06.2006","article-title":"Glucocorticoids increase amyloid-\u03b2 and tau pathology in a mouse model of Alzheimer\u2019s disease","volume":"26","author":"Green","year":"2006","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.psym.2019.11.002_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.biopsych.2012.12.003","article-title":"Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology","volume":"74","author":"Baglietto-Vargas","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.psym.2019.11.002_bib16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/oxfordjournals.aje.a117244","article-title":"Estrogen deficiency and risk of Alzheimer\u2019s disease in women","volume":"140","author":"Paganini-Hill","year":"1994","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.psym.2019.11.002_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/mp.2012.147","article-title":"Associations between gonadotropins, testosterone and beta amyloid in men at risk of Alzheimer\u2019s disease","volume":"19","author":"Verdile","year":"2014","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.psym.2019.11.002_bib18","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1001\/jama.288.17.2123","article-title":"Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County study","volume":"288","author":"Zandi","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.psym.2019.11.002_bib19","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1001\/jama.289.20.2663","article-title":"Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women\u2019s Health Initiative Memory Study: a randomized controlled trial","volume":"289","author":"Rapp","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.psym.2019.11.002_bib20","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.1523\/JNEUROSCI.2514-06.2006","article-title":"Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer\u2019s disease","volume":"26","author":"Rosario","year":"2006","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.psym.2019.11.002_bib21","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1046\/j.1471-4159.2003.02114.x","article-title":"Androgens modulate beta-amyloid levels in male rat brain","volume":"87","author":"Ramsden","year":"2003","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.psym.2019.11.002_bib22","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s12035-014-9078-x","article-title":"Thyrotropin and Alzheimer\u2019s disease risk in the elderly: a systematic review and meta-analysis","volume":"53","author":"Wang","year":"2016","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.psym.2019.11.002_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JAD-2002-4204","article-title":"Thyrotropin releasing hormone (TRH) in the hippocampus of Alzheimer patients","volume":"4","author":"Luo","year":"2002","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.psym.2019.11.002_bib24","first-page":"322","article-title":"Low levels of triiodothyronine in patients with Alzheimer\u2019s disease","volume":"36","author":"Karimi","year":"2011","journal-title":"Iran J Med Sci"},{"key":"10.1016\/j.psym.2019.11.002_bib25","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1212\/WNL.0000000000000382","article-title":"Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy","volume":"82","author":"Westwood","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.psym.2019.11.002_bib26","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.neurobiolaging.2005.09.039","article-title":"Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer\u2019s-like neuropathology in rodents: new cues into the human disease?","volume":"27","author":"Carro","year":"2006","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.psym.2019.11.002_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fphar.2014.00006","article-title":"Vitamin D supplements: a novel therapeutic approach for Alzheimer patients","volume":"5","author":"Annweiler","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.psym.2019.11.002_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/bmb\/ldn013","article-title":"A\u00a0review of Parkinson\u2019s disease","volume":"86","author":"Davie","year":"2008","journal-title":"Br Med Bull"},{"key":"10.1016\/j.psym.2019.11.002_bib29","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/jnc.13691","article-title":"The clinical symptoms of Parkinson\u2019s disease","volume":"139","author":"Sveinbjornsdottir","year":"2016","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.psym.2019.11.002_bib30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000097237","article-title":"Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with Parkinson\u2019s disease","volume":"3","author":"Stypula","year":"1996","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.psym.2019.11.002_bib31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/jnnp-2016-314601","article-title":"Neuroendocrine abnormalities in Parkinson\u2019s disease","volume":"88","author":"De Pablo-Fernandez","year":"2017","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.psym.2019.11.002_bib32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.yfrne.2009.04.014","article-title":"Neuroprotective actions of sex steroids in Parkinson\u2019s disease","volume":"30","author":"Bourque","year":"2009","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.psym.2019.11.002_bib33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.neuropharm.2011.04.031","article-title":"Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson\u2019s disease","volume":"61","author":"Al-Sweidi","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.psym.2019.11.002_bib34","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ane.12334","article-title":"Prolactin and sex hormones levels in males with Parkinson\u2019s disease","volume":"131","author":"Nitkowska","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.psym.2019.11.002_bib35","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.apmr.2006.07.265","article-title":"Bone mineral density in hip-fracture patients with Parkinson\u2019s disease: a case-control study","volume":"87","author":"Di Monaco","year":"2006","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.psym.2019.11.002_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00223-007-9065-6","article-title":"Fracture risk associated with parkinsonism and anti-Parkinson drugs","volume":"81","author":"Vestergaard","year":"2007","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.psym.2019.11.002_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ncl.2014.09.003","article-title":"Huntington disease: pathogenesis and treatment","volume":"33","author":"Dayalu","year":"2015","journal-title":"Neurol Clin"},{"key":"10.1016\/j.psym.2019.11.002_bib38","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.psym.2019.11.002_bib39","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1210\/jc.2008-2543","article-title":"Increased hypothalamic-pituitary-adrenal axis activity in Huntington\u2019s disease","volume":"94","author":"Aziz","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.psym.2019.11.002_bib40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1515\/REVNEURO.2007.18.3-4.223","article-title":"Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington\u2019s disease: clinical consequences and therapeutic implications","volume":"18","author":"Aziz","year":"2007","journal-title":"Rev Neurosci"},{"key":"10.1016\/j.psym.2019.11.002_bib41","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/hmg\/ddl094","article-title":"Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6\/2 transgenic mouse model of Huntington\u2019s disease","volume":"15","author":"Bj\u00f6rkqvist","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.psym.2019.11.002_bib42","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2265.2010.03836.x","article-title":"Altered thyrotropic and lactotropic axes regulation in Huntington\u2019s disease","volume":"73","author":"Aziz","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"Pt 11","key":"10.1016\/j.psym.2019.11.002_bib43","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/brain\/awn244","article-title":"Hypothalamic involvement in Huntington\u2019s disease: an in\u00a0vivo PET study","volume":"131","author":"Politis","year":"2008","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.psym.2019.11.002_bib44","doi-asserted-by":"crossref","first-page":"e4962","DOI":"10.1371\/journal.pone.0004962","article-title":"Neuroendocrine disturbances in Huntington\u2019s disease","volume":"4","author":"Saleh","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.psym.2019.11.002_bib45","first-page":"551","article-title":"Plasma growth hormone concentrations in Huntington\u2019s chorea","volume":"50","author":"Phillipson","year":"1976","journal-title":"Clin Sci Mol Med"},{"key":"10.1016\/j.psym.2019.11.002_bib46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jnnp.41.2.135","article-title":"Growth hormone and prolactin response to bromocriptine in patients with Huntington\u2019s chorea","volume":"41","author":"Chalmers","year":"1978","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.psym.2019.11.002_bib47","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000122878","article-title":"Growth hormone hyperresponsiveness to dopaminergic stimulation in Huntington\u2019s chorea","volume":"28","author":"Muller","year":"1979","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.psym.2019.11.002_bib49","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","article-title":"Amyotrophic lateral sclerosis","volume":"390","author":"van Es","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.psym.2019.11.002_bib50","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0006-8993(88)90126-6","article-title":"Spinal effects of chronic intrathecal administration of the thyrotrophin-releasing hormone analogue (CG 3509) in rats","volume":"455","author":"Fone","year":"1988","journal-title":"Brain Res"},{"key":"10.1016\/j.psym.2019.11.002_bib51","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0022-510X(86)90175-9","article-title":"Concentrations of thyrotropin-releasing hormone in the brain of patients with amyotrophic lateral sclerosis","volume":"76","author":"Mitsuma","year":"1986","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.psym.2019.11.002_bib52","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000074445","article-title":"Neuroendocrinology of neurodegenerative diseases. Insights from transgenic mouse models","volume":"78","author":"Gonzalez De Aguilar","year":"2003","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.psym.2019.11.002_bib53","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1460-9568.1999.00840.x","article-title":"A\u00a0mouse model of familial amyotrophic lateral sclerosis expressing a mutant superoxide dismutase 1 shows evidence of disordered transport in the vasopressin hypothalamo-neurohypophysial axis","volume":"11","author":"Gonz\u00e1lez de Aguilar","year":"1999","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.psym.2019.11.002_bib54","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2265.2006.02609.x","article-title":"Growth hormone secretion is impaired in amyotrophic lateral sclerosis","volume":"65","author":"Morselli","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.psym.2019.11.002_bib55","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1212\/WNL.50.3.772","article-title":"The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis","volume":"50","author":"Torres-Aleman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.psym.2019.11.002_bib56","author":"Chung"},{"key":"10.1016\/j.psym.2019.11.002_bib57","first-page":"1372","article-title":"Frontotemporal dementia: a review for primary care physicians","volume":"82","author":"Cardarelli","year":"2010","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.psym.2019.11.002_bib58","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1192\/bjp.180.2.140","article-title":"Frontotemporal dementia","volume":"180","author":"Snowden","year":"2002","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"10.1016\/j.psym.2019.11.002_bib59","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1212\/01.wnl.0000188759.87240.8b","article-title":"The effects of executive and behavioral dysfunction on the course of ALS","volume":"65","author":"Olney","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.psym.2019.11.002_bib60","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/21678421.2016.1267768","article-title":"Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria","volume":"18","author":"Strong","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.psym.2019.11.002_bib61","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2018.23","article-title":"Physiological changes in neurodegeneration - mechanistic insights and clinical utility","volume":"14","author":"Ahmed","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"Pt 6","key":"10.1016\/j.psym.2019.11.002_bib62","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/brain\/awu075","article-title":"Anatomical correlates of reward-seeking behaviours in behavioural variant frontotemporal dementia","volume":"137","author":"Perry","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.psym.2019.11.002_bib63","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/21678421.2016.1249487","article-title":"The relationship between oestrogen and executive functioning in ALS females with emerging Frontotemporal Lobar Degeneration (FTLD) supports a neuroendocrine model of FTLD attenuation","volume":"18","author":"Flaherty","year":"2017","journal-title":"Amyotroph Lateral Scler Front Degener"},{"key":"10.1016\/j.psym.2019.11.002_bib64","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/jdi.12087","article-title":"Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies","volume":"4","author":"Gudala","year":"2013","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.psym.2019.11.002_bib65","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1474-4422(05)70284-2","article-title":"Risk of dementia in diabetes mellitus: a systematic review","volume":"5","author":"Biessels","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.psym.2019.11.002_bib66","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3233\/JAD-160163","article-title":"Interaction between midlife blood glucose and APOE genotype predicts later Alzheimer\u2019s disease pathology","volume":"53","author":"Bangen","year":"2016","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"Suppl 1","key":"10.1016\/j.psym.2019.11.002_bib67","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.neurobiolaging.2005.08.021","article-title":"Insulin resistance syndrome and Alzheimer\u2019s disease: age- and obesity-related effects on memory, amyloid, and inflammation","volume":"26","author":"Craft","year":"2005","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.psym.2019.11.002_bib68","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.neuroscience.2018.06.018","article-title":"Insulin-signaling pathway regulates the degradation of amyloid \u03b2-protein via astrocytes","volume":"385","author":"Yamamoto","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.psym.2019.11.002_bib69","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fendo.2014.00161","article-title":"Insulin in the brain: its pathophysiological implications for states related with central insulin resistance, type 2 diabetes and Alzheimer\u2019s disease","volume":"5","author":"Bl\u00e1zquez","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.psym.2019.11.002_bib70","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/JAD-2005-7107","article-title":"Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer\u2019s disease\u2013is this type 3 diabetes?","volume":"7","author":"Steen","year":"2005","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.psym.2019.11.002_bib71","first-page":"1421430","article-title":"Metformin alleviated abeta-induced apoptosis via the suppression of JNK MAPK signaling pathway in cultured hippocampal neurons","volume":"2016","author":"Chen","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.psym.2019.11.002_bib72","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/00207454.2015.1015722","article-title":"The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer\u2019s disease and mild-to-moderate Alzheimer\u2019s disease: a meta-analysis","volume":"126","author":"Cheng","year":"2016","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.psym.2019.11.002_bib73","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.psym.2019.11.002_bib74","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1586\/ern.11.152","article-title":"The association of diabetes and dementia and possible implications for nondiabetic populations","volume":"11","author":"Ravona-Springer","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.psym.2019.11.002_bib75","doi-asserted-by":"crossref","first-page":"93","DOI":"10.15277\/bjd.2017.139","article-title":"Management of diabetes and dementia","volume":"17","author":"Puttanna","year":"2017","journal-title":"Br J Diabetes"},{"key":"10.1016\/j.psym.2019.11.002_bib76","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.mehy.2008.05.036","article-title":"Subclinical Cushing\u2019s syndrome is a potential cause of metabolic dementia and rapidly progressive Alzheimer-type dementia","volume":"71","author":"Guldiken","year":"2008","journal-title":"Med Hypotheses"},{"issue":"Pt A","key":"10.1016\/j.psym.2019.11.002_bib77","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.expneurol.2016.06.028","article-title":"Corticosterone dysregulation exacerbates disease progression in the R6\/2 transgenic mouse model of Huntington\u2019s disease","volume":"283","author":"Dufour","year":"2016","journal-title":"Exp Neurol"}],"container-title":["Psychosomatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318219302233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318219302233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:27:15Z","timestamp":1758500835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033318219302233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0033318219302233"],"URL":"https:\/\/doi.org\/10.1016\/j.psym.2019.11.002","relation":{},"ISSN":["0033-3182"],"issn-type":[{"value":"0033-3182","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroendocrine Disturbances in Neurodegenerative Disorders: A Scoping Review","name":"articletitle","label":"Article Title"},{"value":"Psychosomatics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psym.2019.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Academy of Consultation-Liaison Psychiatry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}